{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:59:37Z","timestamp":1793203177419,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104314"],"award-info":[{"award-number":["82104314"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007847","name":"Jilin Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["YDZJ202301ZYTS034"],"award-info":[{"award-number":["YDZJ202301ZYTS034"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jhep.2024.12.006","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T03:05:11Z","timestamp":1734577511000},"page":"967-978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study"],"prefix":"10.1016","volume":"82","author":[{"given":"Lin","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-0500","authenticated-orcid":false,"given":"Lin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8398-1882","authenticated-orcid":false,"given":"Jiangyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1639-0215","authenticated-orcid":false,"given":"Can","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyue","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2320-4404","authenticated-orcid":false,"given":"Yanhua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhep.2024.12.006_bib1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.12.006_bib2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.12.006_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154770","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","volume":"119","author":"Muzurovic","year":"2021","journal-title":"Metab Clin Exp"},{"issue":"6","key":"10.1016\/j.jhep.2024.12.006_bib4","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.006_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic fatty liver disease: pathogenesis and disease spectrum","volume":"11","author":"Hardy","year":"2016","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"10.1016\/j.jhep.2024.12.006_bib6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","article-title":"Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study","volume":"165","author":"Huang","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.12.006_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev-physiol-021113-170315","article-title":"Glucagon-like peptide-1: glucose homeostasis and beyond","volume":"76","author":"Cho","year":"2014","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"10.1016\/j.jhep.2024.12.006_bib8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s42255-020-00327-x","article-title":"Metabolic Messengers: glucagon-like peptide 1","volume":"3","author":"Gribble","year":"2021","journal-title":"Nat Metab"},{"issue":"6","key":"10.1016\/j.jhep.2024.12.006_bib9","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Ben-Shlomo","year":"2011","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.12.006_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167952","article-title":"Dual gut hormone receptor agonists for diabetes and obesity","volume":"133","author":"Bass","year":"2023","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.jhep.2024.12.006_bib11","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jhep.2024.12.006_bib12","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.jhep.2024.12.006_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic messengers: FGF21","volume":"3","author":"Flippo","year":"2021","journal-title":"Nat Metab"},{"issue":"8","key":"10.1016\/j.jhep.2024.12.006_bib14","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.cgh.2023.03.041","article-title":"Clinical trial landscape in NASH","volume":"21","author":"Harrison","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2024.12.006_bib15","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.jhep.2024.12.006_bib16","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"The Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.12.006_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7150\/ijbs.73936","article-title":"Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine","volume":"19","author":"Tan","year":"2023","journal-title":"Int J Biol Sci"},{"issue":"4","key":"10.1016\/j.jhep.2024.12.006_bib18","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/hep.31856","article-title":"Hepatic fibroblast growth factor 21 is involved in mediating functions of liraglutide in mice with dietary challenge","volume":"74","author":"Liu","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.006_bib19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ebiom.2019.02.037","article-title":"Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output","volume":"41","author":"Liu","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhep.2024.12.006_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103202","article-title":"A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis","volume":"63","author":"Pan","year":"2021","journal-title":"EBioMedicine"},{"issue":"20","key":"10.1016\/j.jhep.2024.12.006_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults","volume":"330","author":"Elmaleh-Sachs","year":"2023","journal-title":"Jama"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2024.12.006_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials","volume":"20","author":"Aroda","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.jhep.2024.12.006_bib23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/bcp.12676","article-title":"Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study","volume":"80","author":"Dong","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jhep.2024.12.006_bib24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.jhep.2024.12.006_bib25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10213","key":"10.1016\/j.jhep.2024.12.006_bib26","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.jhep.2024.12.006_bib27","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.jhep.2024.12.006_bib28","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.12.006_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2337\/dc15-0165","article-title":"A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes","volume":"39","author":"Nauck","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.jhep.2024.12.006_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"The Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.jhep.2024.12.006_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"New Engl J Med"},{"issue":"11","key":"10.1016\/j.jhep.2024.12.006_bib32","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.jhep.2024.12.006_bib33","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cel Metab."},{"issue":"4","key":"10.1016\/j.jhep.2024.12.006_bib34","article-title":"AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients","volume":"1","author":"Kaufman","year":"2020","journal-title":"Cel Rep Med"},{"issue":"1","key":"10.1016\/j.jhep.2024.12.006_bib35","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1210\/clinem\/dgab624","article-title":"LLF580, an FGF21 analog, reduces triglycerides and hepatic fat in obese adults with modest hypertriglyceridemia","volume":"107","author":"Rader","year":"2022","journal-title":"The J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jhep.2024.12.006_bib36","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s42255-019-0041-z","article-title":"Metabolic messengers: adiponectin","volume":"1","author":"Straub","year":"2019","journal-title":"Nat Metab"},{"issue":"7","key":"10.1016\/j.jhep.2024.12.006_bib37","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1172\/JCI29126","article-title":"Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome","volume":"116","author":"Kadowaki","year":"2006","journal-title":"J Clin Invest"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824027582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824027582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:02:13Z","timestamp":1773457333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824027582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0168827824027582"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.12.006","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}